The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer.
about
Differential PKA activation and AKAP association determines cell fate in cancer cellsRecent developments in receptor tyrosine kinases targeted anticancer therapyEvasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.miRNA Alterations Modify Kinase Activation In The IGF-1 Pathway And Correlate With Colorectal Cancer Stage And Progression In PatientsPhase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastaticExpression Profiles of the Insulin-like Growth Factor System Components in Liver Tissue during Embryonic and Postnatal Growth of Erhualian and Yorkshire Reciprocal Cross F1 Pigs.Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approachExpression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study.Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells.Amplification of the insulin-like growth factor 1 receptor gene is a rare event in adrenocortical adenocarcinomas: searching for potential mechanisms of overexpressionDopamine, by acting through its D2 receptor, inhibits insulin-like growth factor-I (IGF-I)-induced gastric cancer cell proliferation via up-regulation of Krüppel-like factor 4 through down-regulation of IGF-IR and AKT phosphorylationTargeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and ExpectationsTherapeutic destruction of insulin receptor substrates for cancer treatment.An insulin-like growth factor 1 receptor inhibitor induces CYP3A4 expression through a pregnane X receptor-independent, noncanonical constitutive androstane receptor-related mechanism.Adrenocortical stem and progenitor cells: implications for adrenocortical carcinomaPrognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer.Clinical significance of insulin-like growth factor gene polymorphisms with survival in patients with gastrointestinal stromal tumorsGlycemic Index, Glycemic Load, and Lung Cancer Risk in Non-Hispanic Whites.Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms.Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro.Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects.Indole-3-carbinol disrupts estrogen receptor-alpha dependent expression of insulin-like growth factor-1 receptor and insulin receptor substrate-1 and proliferation of human breast cancer cells.Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastomaIgf1r as a therapeutic target in a mouse model of basal-like breast cancerType I insulin-like growth factor receptor induces pulmonary tumorigenesis.The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors.Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission.Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini reviewNovel targets in esophageal and gastric cancer: beyond antiangiogenesis.Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression.New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and future.Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies.The impact of obesity on breast cancer: a retrospective review.Current and future management strategies for relapsed or progressive hepatoblastoma.IGF-IR and its inhibitors in gastrointestinal carcinomas (Review).Monoclonal antibodies in oncology therapeutics: present and future indications.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.
P2860
Q24337554-CDDF854A-DFA7-4465-915E-88FC74BFEF99Q26751331-65B0DAAB-9188-4E4A-9A17-763BEB161D13Q26827810-FD7D0FAF-4E59-4477-B6F8-C99D31E570F7Q28392422-364A09FA-C54D-48C3-98B1-99AB0B26C0F1Q33402421-8E4FFD80-E7B1-44F4-9042-FE2400F42F1EQ33414971-C36CF6E4-FBD4-4691-8162-96B9BFF821D8Q33884308-27B4AABA-0C25-47E8-B7FB-48268C48B9CBQ33925323-6DB04514-C5D4-41A2-ACB8-45E48C76ABA5Q33957406-E4E6FB48-ABD1-4972-B0CB-BF7572F951A4Q33980773-D2A56D14-7DA7-46ED-8842-20BE5CB10C94Q33993253-E89DD332-7017-4CF2-9200-36590ADE3AB8Q34358346-3FF0122E-89A8-4B95-B17D-A7EB2B62E842Q35013284-D18FB585-7558-4587-8A31-E81ACC5847F3Q35343877-A355C6BB-084F-452E-AEA0-FFC8678CE210Q35776828-E574F30E-733E-4564-8568-0D25840B2691Q35782788-0296BCAF-7215-47C2-AFF0-6F41A7941F36Q35819793-98437B63-C9E2-49B4-80AF-44040BECF4A9Q35925906-3439BAA3-FA86-4195-8B0F-561CB6CA3E18Q35946401-5E3D685D-D7D9-43D7-8D05-214712CC974DQ36023488-24F20FAD-7956-45A3-B46F-785B343EC797Q36208187-14ACD871-A27E-4FB8-A299-D2358BC1621BQ36685345-0D1E43A0-65F6-4036-A2EB-6BBBDFF3530AQ36685485-0C99DB02-9A7F-4A7B-BDB5-B78357034D7EQ36934457-88D5ECE9-416B-4F63-B624-4A8A7AA38882Q37010551-3649FE6F-3BBA-4B89-902A-06FBCD1DF711Q37114859-460AEEFB-CED9-485B-916C-D269F89A5DFDQ37229930-A27E43ED-605C-45AC-984E-C0D8236B712FQ37279733-F073A49E-9074-4578-A5F2-1427EC7B744CQ37286014-7CE6B7BA-E3A2-4E37-820B-CF8288C88C65Q37418930-D4CC289D-E3BA-4607-8912-FF78AE42D094Q37566645-26CB6F2F-C0BA-4983-8122-E0C24CC3506BQ37694786-B5AB4F48-7987-450C-BD69-AFA993652F62Q37850810-4D09C046-965A-4F21-A79A-93EC1AEF1476Q37889961-7FFA8959-CDBA-4146-9EFC-557EFB100DBEQ37903335-86C6B908-4D5E-4B0C-83E1-33D5B5C37E3DQ37997377-41DC186F-74E6-436C-88E0-A04B78BDFCBDQ38019027-BD7252A0-47D7-43A9-B61B-CBAF77596CBCQ38042423-5BD05BFD-AFAE-437B-97A8-E5646C1B53BAQ38071374-993B281F-AEB6-4420-9DC8-36BDD5F9D95EQ38989374-61E12080-D4EB-4B09-93FC-B8A2986187B6
P2860
The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The emerging role of the insul ...... therapeutic target in cancer.
@en
The emerging role of the insul ...... therapeutic target in cancer.
@nl
type
label
The emerging role of the insul ...... therapeutic target in cancer.
@en
The emerging role of the insul ...... therapeutic target in cancer.
@nl
prefLabel
The emerging role of the insul ...... therapeutic target in cancer.
@en
The emerging role of the insul ...... therapeutic target in cancer.
@nl
P1433
P1476
The emerging role of the insul ...... therapeutic target in cancer.
@en
P2093
Paul E Goss
Paula D Ryan
P356
10.1634/THEONCOLOGIST.2007-0199
P577
2008-01-01T00:00:00Z